Form 4: DexCom Executive Executes Planned Stock Sale

EVP and Chief Commercial Officer Jon Coleman sold 9,823 shares of DexCom common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jon Coleman, EVP and Chief Commercial Officer of DexCom, sold a total of 9,823 shares of common stock.
• The sales occurred on June 3, 2026 (4,912 shares at $73.00) and June 4, 2026 (4,911 shares at $74.13).
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026.
• Following these transactions, the reporting person retains beneficial ownership of 95,450 shares, all of which are unvested restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents standard executive financial management.

Positives

• The sale was conducted under a pre-established 10b5-1 plan, indicating the transaction was automated and not based on non-public information.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Continued reliance on equity-based compensation for key executives may lead to periodic selling pressure as units vest and are sold.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Management Comments

• The transactions were executed pursuant to a 10b5-1 plan intended to allow for the orderly disposition of shares.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate governance practice and typically does not signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at large-cap medical device companies like Abbott Laboratories and Medtronic to manage personal liquidity while avoiding insider trading concerns.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed via a pre-planned, automated mechanism.

Next Steps

• Future vesting of restricted stock units scheduled through March 2029 and May 2029.

Key Dates

Keywords

DexCom, DXCM, Insider Trading, Form 4, 10b5-1, Executive Compensation